$EMED There’s no direct information indicating EMED is actively pursuing or likely to execute a RS. I think its core strategy is to improve its financial health and increase its stock price by restructuring its capital, rather than directly implementing a RS. It appears that things will ramp up in October.
The company’s recent focus has been on financial restructuring, including the appointment of new board members and advisors, new distribution agreements, preliminary purchase orders, and updates on the WellnessPro Infinity device.
EMED faced challenges in the manufacturing of the WellnessPro Infinity device due to global supply chain disruptions, shortages of high-demand components like microcontrollers, and rigorous European manufacturing standards. They also experienced delays in plastic manufacturing but adapted by finding a new manufacturing partner to ensure quality.
Bullish
Market Data 
Markets 
AI
